New Remedica CEO Andrew Bird addresses Employee Town Hall

The new CEO of Cyprus-headquartered pharmaceutical company Remedica, Andrew Bird, recently addressed the business’ second quarterly Employee Town Hall of the year, introducing himself to his new colleagues.

Having joined the company as a Board Member and CEO earlier this month, Bird, according to his LinkedIn page, was previously CEO of Acino in the UAE for over six years after spending over seven years at Bristol-Myers Squibb, also in the UAE. He had earlier in his career also worked at companies including PhRMA, Pfizer and the Janssen Pharmaceutical Companies of Johnson & Johnson among others, in significant posts that saw him working around the world.

Founded in 1980 as a family enterprise, Remedica has evolved into a prominent privately owned enterprise and one of the leading pharmaceutical producers in the European Union. Since 2023, Remedica has belonged to L1 Health, an international investment holding focused on developing healthcare assets globally.

In a LinkedIn post, Remedica noted that its recent second quarterly Employee Town Hall of the year “was a special one.”

According to the post, “ It marked the first town hall with our new CEO, Andrew Bird, who took the time to introduce himself, share his story, and connect with the team on a personal level.”

The company “also looked back at a strong Q1, celebrating our wins, as well as recognising the challenges we overcame.”
“Another highlight,” the company’s post continued, “was of course our employee awards, where we celebrated the individuals who went above and beyond last quarter, demonstrating outstanding dedication, teamwork and impact.”
“ Looking ahead, we discussed what’s next for the rest of 2025 – our strategic priorities, growth plans, and the opportunities we are excited to pursue together. With a solid first quarter, new leadership, and a shared sense of purpose, the energy across the company is high!,” the post concluded.